Stay updated on Nivolumab Ibrutinib in CLL Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Ibrutinib in CLL Clinical Trial page.

Latest updates to the Nivolumab Ibrutinib in CLL Clinical Trial page
- Check6 days agoChange DetectedThe page now shows Revision: v3.6.5, replacing Revision: v3.6.4. This indicates an updated version of the study record.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check21 days agoChange DetectedSoftware revision updated from v3.6.3 to v3.6.4, indicating a new site release. No visible changes to the study details content or page structure are shown.SummaryDifference0.0%

- Check28 days agoNo Change Detected
- Check42 days agoChange DetectedA new revision tag (v3.6.3) was added and the previous tag (v3.6.2) removed, indicating a minor platform update; the visible study details and layout remain unchanged.SummaryDifference0.0%

- Check49 days agoChange DetectedThe page's Revision tag was updated from v3.6.0 to v3.6.2, indicating a minor site update to the study page. This reflects a version bump in the page's content rather than a change to the study data or eligibility.SummaryDifference0.0%

- Check63 days agoChange DetectedThe page now includes an explicit recruitment update 'No longer looking for participants' and adds user guidance sections 'How to Read a Study Record', 'Common Questions', and 'How to Join a Study'. The header 'Intervention/Treatment' is introduced (replacing 'Intervention / Treatment'), and a 'Revision: v3.6.0' tag appears alongside removal of 'Revision: v3.5.5'.SummaryDifference0.4%

- Check70 days agoChange DetectedThe page's revision label has been updated from v3.5.4 to v3.5.5. This update represents a newer version of the page's revision history without modifying the study details or results.SummaryDifference0.0%

Stay in the know with updates to Nivolumab Ibrutinib in CLL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Ibrutinib in CLL Clinical Trial page.